An observational study in Acute Lymphoblastic Leukemia, Leukemia and Non-Hodgkin's Lymphoma, sponsored by Goethe University. Recruiting at 147 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-05.
Sponsored by Goethe University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by Goethe University — 2 open to participants now, 3 under way, none of them phase 3. Precursor Cell Lymphoblastic Leukemia-Lymphoma · Goethe University.
Among the 16 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by Goethe University, this one is the only one that started in 2009, is the only observational one, and was the 12th registered.
2,584 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 473 are open to participants now.
Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →2 of the 16 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by Goethe University are open now, in 2 countries. Recruiting first, the newest first:
Goethe University · Sites in Germany
Ages 18–65
By country, each count listing its studies:
Of the 370 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (69%) stop at 75 or younger; 247 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 7 · Phase 3 3 · Phase 4 5
First in 1993; this study’s year is marked. 1 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 10,000 is above the median of 108 across 400 observational studies indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma.
Median enrollment 80 across the 15 interventional studies, 10,000 across the 1 observational. Of the 13 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Goethe University is the lead sponsor of 98 studies on the registry; 15 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 16 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by Goethe University, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The GMALL registry serves the purpose of ALL research and quality assurance. The Registry collects data about diagnostics, treatment and outcome of Adult ALL Patients in the clinical routine, whether or not the patient is treated within a clinical trial.
Acute Lymphoblastic Leukemia or seleted NHL
Inclusion Criteria:
Overall survival
Time frame: up to 10 years
Event free survival
Time frame: up to 10 years
Hematologic remission rate
Time frame: after induction and consolidation, approximately 6 - 8 weeks from diagnosis
Molecular remission rate
Time frame: after induction and consolidation, approximately 6 - 8 weeks from diagnosis
Positron Emission Tomography (PET) based remission evaluation
Time frame: after induction and consolidation, approximately 6 - 8 weeks from diagnosis
Remission duration
Time frame: up to 10 years
Relapse rate
Time frame: up to 10 years
Disease free survival
Time frame: up to 10 years
Early mortality
Time frame: during induction therapy with a duration of approximately 6 - 8 weeks
Mortality in Clinical Remission (CR)
Time frame: up to 10 years
Comorbidities
Time frame: Time of diagnosis and up to 10 years during regular follow-up requests which are not pre-specified
Quality of life assessed by Quality of Life Questionnaire (QLQ-C30)
Time frame: after treatment which is approximately 2.5 years from diagnosis
Eastern Cooperative Oncology Group (ECOG) status
Time frame: Time of diagnosis and up to 10 years during regular follow-up requests which are not pre-specified
Toxicities assessed by CTCAE v4.03
Time frame: during treatment with an approximate duration of 2.5 years from diagnosis
Showing the first 100 of 147 sites across 2 countries. Choose a country and city above to see the rest.
Plan to share: No
No publications or documents are linked to this record.
The record gives a start of Feb 2009, a primary completion of Dec 2030 and a completion of Dec 2035. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Precursor Cell Lymphoblastic Leukemia-Lymphoma →
Goethe University